GB18 injection for tumor cachexia in cancer patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a Phase 1, open-label, multiple-ascending-dose trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of GB18 in Chinese adults with tumor cachexia and non-resectable or advanced solid tumors. The study will enroll 18-36 participants across three dosing levels, with a 12-week treatment and follow-up period. Participants will undergo safety assessments, vital signs, ECGs, labs, and blood sampling to characterize how GB18 behaves in the body and its potential effects on cachexia. The trial aims to determine safe dosing and gather early signals of efficacy in improving anorexia and weight-related outcomes.

Why it matters

Who can join: the full rules

Key Inclusion Criteria:

* Voluntarily serve as a participant and sign the informed consent form;
* Age ≥ 18 years;
* Histologically or cytologically confirmed, non-resectable, locally advanced, recurrent, or metastatic solid tumors with failed standard treatment or have no standard treatment options. This includes, but is not limited to, colorectal cancer, pancreatic cancer, gastric cancer, esophageal cancer, biliary tract cancer, non-small cell lung cancer, prostate cancer, breast cancer, or ovarian cancer.
* Diagnosed with cancer cachexia: BMI \< 18.5 kg/m², and no unintentional weight loss \> 2% within 6 months before screening, or no unintentional weight loss \> 5% within 6 months before screening regardless of BMI.
* A serum GDF15 concentration ≥ 1.5 ng/mL.
* Laboratory Test Requirements:

  1. Absolute neutrophil count ≥ 1.0 × 10⁹/L, platelet count ≥ 75 × 10⁹/L, hemoglobin ≥ 80 g/L.
  2. Serum creatinine ≤ 1.5 × ULN (Upper Limit of Normal).
  3. Total bilirubin ≤ 1.5 × ULN, AST and ALT ≤ 3 × ULN (or ≤ 5 × ULN for patients with liver metastasis).
  4. Activated partial thromboplastin time ≤ 1.5 × ULN, International Normalized Ratio ≤ 1.5.
  5. Left Ventricular Ejection Fraction \> 50% as assessed by echocardiogram.
* Eastern Cooperative Oncology Group (ECOG) performance status score: 0-2 points
* Expected survival period ≥ 4 months.

Key Exclusion Criteria:

* Known active/symptomatic central nervous system metastases and/or carcinomatous meningitis.
* Plan to receive radiotherapy as a component of the primary antitumor treatment regimen.
* BMI \> 26 kg/m².
* Presence of reversible causes for reduced food intake, including but not limited to NCI CTCAE grade 3 or 4 oral mucositis; NCI CTCAE grade 3 or 4 nausea, vomiting, diarrhea, or constipation; mechanical obstruction preventing oral intake.
* Comorbid conditions unrelated to tumor cachexia that cause difficulty in eating or malabsorption.
* Cachexia due to other investigator-determined or clearly defined causes. History within the past 6 months of any of the following: myocardial infarction, congenital long QT syndrome, second- or third-degree atrioventricular block, arrhythmias (including sustained ventricular tachycardia or ventricular fibrillation), unstable angina, acute coronary syndrome, symptomatic congestive heart failure (NYHA class III or IV) of coronary or peripheral origin, stroke, transient ischemic attack, or symptomatic pulmonary embolism or other clinically significant thromboembolic disease.
* Hypertension with unsatisfactory control despite antihypertensive therapy (defined as systolic blood pressure \> 150 mmHg or diastolic blood pressure \> 90 mmHg).
* Patients receiving tube feeding or parenteral nutrition (total or partial) within 28 days before the first administration of the investigational drug.
* Initiation of new systemic glucocorticoid therapy from 28 days before the first dose of the investigational drug to the end of the study.
* Major surgery not yet recovered from within 28 days before the first dose of the investigational drug (central venous access placement and tumor biopsy are not considered major surgery), or anticipated major surgery during the study period.
* Prior participation in clinical trials targeting the GDF-15/GFRAL signaling pathways, or receipt of other investigational agents within 28 days or five half-lives (whichever is shorter) before the first dose of the investigational drug.
* Severe infection requiring intravenous antibiotics, antivirals, or antifungal agents within 14 days before the first dose of the investigational drug.

Where it's running

• Peking University Cancer Hospital
  Beijing, Beijing Municipality, China Recruiting
• Beijing GoBroad Hospital
  Beijing, Beijing Municipality, China Recruiting

Study contacts

• Study coordinator: Jinhai Lin
• Email: linjinhai@kexing.com
• Phone: 400-888-9496

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• DS010 in advanced cancer with cachexia: safety and early signals in adults

  This study tests DS010 in adults with cancer and cachexia to see if it is safe and whether it might help with their condition.

  Recruiting at 4 sites Phase 1/2 Dartsbio Pharmaceuticals Ltd. · Concord West, New South Wales and 3 other locations · NCT07921576

• Spatial multi-omics and AI-based early warning for pancreatic cancer cachexia

  This study tests whether spatial multi-omics data can reveal how the tumor and body metabolism interact in pancreatic cancer cachexia and whether a multimodal AI model can predict cachexia early in adults with pancreatic ductal adenocarcinoma.

  Recruiting Peking Union Medical College Hospital · Beijing · NCT07670286

• Pathogenesis and Reversal Strategies for Cancer Cachexia Using Multi-Omics

  This study uses multiple omics methods and nutritional interventions to try to find causes and reversal strategies for cachexia in adults with gastrointestinal cancers.

  Recruiting China Medical University, China · Shenyang, Liaoning · NCT07519837

• Nanocrystalline megestrol acetate with chemoradiation for locally advanced cervical cancer

  This Phase 1 trial tests whether taking nanocrystalline megestrol acetate by mouth can prevent or reduce weight and muscle loss in adults with locally advanced cervical cancer who are receiving concurrent chemoradiotherapy.

  Recruiting Phase 1 Second Xiangya Hospital of Central South University · Changsha, Hunan · NCT07338487

• ASCA101 for cancer-related cachexia

  This study tests ASCA101 at two doses to see if it helps weight gain in people with solid tumors and cachexia.

  Recruiting at 6 sites Phase 2 MetaFines · Seoul, Gangnam-gu and 5 other locations · NCT07168226

• How body composition and psychosocial health relate to outcomes for people receiving immune checkpoint inhibitors

  This project will see if body composition, psychosocial health, and medication-related problems affect side effects, treatment response, and quality of life in adults with cancer treated with immune checkpoint inhibitors.

  Recruiting Hacettepe University · Ankara, Altındağ · NCT07130981

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.